Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.
Also called NCT04942834
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 320 participants
- Sponsor
- Registry
-
NCT04942834
-
- Other papers using this trial's data
- Cryoballoon ablation vs. antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicentre randomized CEPAF trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04942834. Randomized; no masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2025-08-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
- Acronym
- Cryo-InitialAF
- Condition
- Atrial Fibrillation, Persistent
- Condition
- Arrhythmias, Cardiac
- Intervention (Drug)
- Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone
- Intervention (Device)
- cryoballoon ablation
- Lead sponsor
- Ruijin Hospital
Record details
- Record id
cardio:ct-nct04942834- Content hash
d492f65ac34a636a8f272cc13c5c98b1959bcb4cabc4370337eacfd75e0f405c